Company acquires exclusive rights to HIV antibody
BY Advocate.com Editors
May 15 2003 12:00 AM ET
Rockville, Md.-based Human Genome Sciences on Monday acquired exclusive rights to an antibody that could be used to slow HIV replication in the bodies of HIV-positive people, The Baltimore Sun reports. Under a licensing deal with Angenix, a California pharmaceutical company, HGS gained exclusive rights to the CCR5 mAb antibody, which prevents cellular HIV infection by jamming a key receptor on the surface of immune system cells that HIV must latch on to in order to enter the cells. A Phase I clinical trial of the antibody is planned to begin later this year.
- EXCLUSIVE: Bette Midler Covers TLC's 'Waterfalls'
- #TBT: They Died in the Closet
- Gay Artists & Artwork From Around the Globe | Artist Spotlight
- Op-ed: How Transparent Tried and Failed to Represent Trans Men
- That's Amoré! 11 Irresistible Images of What Happened When Rome Recognized Same-Sex Marriages
- Playwright Responds to N.C. High School That Canceled Play Due to Gay Scene